Market Herald logo


Be the first with the news that moves the market
  • Waverley Pharma (WAVE) has appointed a new company President and CEO.
  • Larry Thiessen took on the role as of February 1st 2020.
  • Waverley Pharma has also authorised the grant of an aggregate 250,000 stock options to certain company directors and officers.
  • Waverley Pharma’s share price remains steady, with shares trading at $0.10 apiece.

Pharmaceutical company Waverley Pharma’s (WAVE) board of directors has appointed Larry Thiessen as the new President and CEO. This new appointment went into effect on February 1st 2020.

Mr Thiessen, who has a Bachelor of Science in Biology and an Executive M.B.A., has decades of experience working in the pharmaceutical industry.

Formerly of Bausch Health Companies Inc (or Biovail Corporation), Mr Thiessen climbed the ladder from manager to site director of the manufacturing operation in Steinbach, Manitoba. He led roughly 400 people in that capacity.

Company Chairman, Dr Albert Friesen, said “The board is very pleased to welcome Larry to lead Waverley Pharma into the future. We look forward to working with him as he brings his extensive knowledge and leadership experience to the company.”

Waverley Pharma has also announced that it has authorised the grant of stock options to certain directors and officers of the company, including Mr Thiessen.

The grant is for an aggregate 250,000 stock options, each of which will be exercisable into one common share of the company.

Those shares will be available at what the closing market price of the company’s common shares were on the date of grant, for 5 years from the same date.

Waverley Pharma’s share price remains steady, with shares trading at $0.10 apiece.

More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" BioSyent reports Q1 2023 financial results

BioSyent (TSXV:RX) released its financial results for the three months ended March 31, 2023.

" Highmark Interactive approved for reimbursement services of remote patient monitoring devices

Highmark Interactive (V.HMRK) has been processed for remote patient monitoring and reimbursed by Medicare for those services.

" New data to be highlighted at the world’s top cancer conference

Next week, top health care firms will converge or the biggest cancer conference in the world.